TY - JOUR
T1 - Peripheral neuropathy in children and adolescents treated for cancer
AU - Bjornard, Kari L.
AU - Gilchrist, Laura S.
AU - Inaba, Hiroto
AU - Diouf, Barthelemy
AU - Hockenberry, Marilyn J.
AU - Kadan-Lottick, Nina S.
AU - Bowers, Daniel C.
AU - Dolan, M. Eileen
AU - Ullrich, Nicole J.
AU - Evans, William E.
AU - Ness, Kirsten K.
N1 - Funding Information:
KLB, HI, BD, MJH, NSK-L, DCB, MED, NJU, WEE, and KKN are recipients of US National Institutes of Health funding through their institutional cancer centre grant or individual grants. There was no funding source for this study.
Publisher Copyright:
© 2018 Elsevier Ltd
PY - 2018/10
Y1 - 2018/10
N2 - Peripheral neuropathy is a well recognised treatment-related toxicity in children with cancer, associated with exposure to neurotoxic chemotherapy agents. Acute damage can occur in sensory, motor, or autonomic neurons, with symptoms that are rarely life threatening, but often severe enough to interfere with function during therapy and after treatment ends. The type of neuropathy and specific symptoms are associated with multiple factors including age at time of therapy, genetic predisposition, chemotherapy type and cumulative dose, and exposure to other agents during therapy. In this Review, we describe the peripheral neuropathy phenotype in children during cancer therapy and among survivors who have completed therapy, to summarise genetic and treatment-related risk factors for neuropathy, and to outline strategies to monitor and detect neuropathy during and after therapy. Additionally, we outline strategies for medical management of neuropathy during treatment and potential rehabilitation interventions to prevent or remediate functional loss.
AB - Peripheral neuropathy is a well recognised treatment-related toxicity in children with cancer, associated with exposure to neurotoxic chemotherapy agents. Acute damage can occur in sensory, motor, or autonomic neurons, with symptoms that are rarely life threatening, but often severe enough to interfere with function during therapy and after treatment ends. The type of neuropathy and specific symptoms are associated with multiple factors including age at time of therapy, genetic predisposition, chemotherapy type and cumulative dose, and exposure to other agents during therapy. In this Review, we describe the peripheral neuropathy phenotype in children during cancer therapy and among survivors who have completed therapy, to summarise genetic and treatment-related risk factors for neuropathy, and to outline strategies to monitor and detect neuropathy during and after therapy. Additionally, we outline strategies for medical management of neuropathy during treatment and potential rehabilitation interventions to prevent or remediate functional loss.
UR - http://www.scopus.com/inward/record.url?scp=85054861074&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054861074&partnerID=8YFLogxK
U2 - 10.1016/S2352-4642(18)30236-0
DO - 10.1016/S2352-4642(18)30236-0
M3 - Review article
C2 - 30236383
AN - SCOPUS:85054861074
SN - 2352-4642
VL - 2
SP - 744
EP - 754
JO - The Lancet Child and Adolescent Health
JF - The Lancet Child and Adolescent Health
IS - 10
ER -